Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (24)	2/14/2002 10:05:20 AM
From: nigel bates	Read Replies (1) \| Respond to of 510

Ciphergen and Aaron Diamond AIDS Research Center Announce Drug Discovery Research Collaboration FREMONT, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - news) announced today that it has signed a Research and License Agreement with the Aaron Diamond AIDS Research Center (ADARC). This agreement contains detailed workplans to pursue projects related to discoveries and samples provided by Aaron Diamond, as well as joint discoveries. As part of the Agreement, Ciphergen retains therapeutic and diagnostic rights to discoveries made under the collaboration, with royalties paid back to ADARC. A small percentage of HIV-infected individuals do not develop AIDS, even after many years. Those HIV-infected individuals who remain healthy are termed ``non-progressors,'' and it is thought that a soluble factor secreted by CD8+ cytotoxic T lymphocytes may play a role in the differing course of their disease. Thus, many researchers have attempted to identify the soluble factors secreted by the cytotoxic T cells of these special patients. Several candidate protein biomarkers were found by Dr. Linqi Zhang (ADARC) and Dr. John Mei (Ciphergen) during a demonstration of the ProteinChip® System to the ADARC, resulting in this collaboration. ``While the list of endogenously produced antiviral proteins continues to grow, the application of these biomarkers to patient management and care has been limited due to the lack of systematic studies that validate their clinical utility,'' stated Dr. David Ho, Scientific Director and CEO of ADARC. ``We are undertaking this collaborative research effort in the hopes of identifying serum proteins with these characteristics that could become antiviral agents themselves, or prove to be unique targets for future drug development.'' ``We're extremely pleased to be working with the Aaron Diamond AIDS Research Center, one of the world's leading AIDS research groups,'' stated William E. Rich, President and CEO of Ciphergen. ``We believe this collaborative research effort can lead to advances in the understanding of the molecular basis of AIDS progression and the potential for drug discovery.''...